FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.815,92 -570,17 (-1,49%) Nasdaq
15.657,82 -325,26 (-2,04%) Nikkei 225
38.340,46 -65,20 (-0,17%) Petrolio
81,15 -0,78 (-0,95%) Bitcoin EUR
56.388,23 -3.068,59 (-5,16%)
Crescita Therapeutics Inc. (CRRTF)
Crescita Therapeutics Inc.
2805 Place Louis-R Renaud
Laval, QC H7V 0A3
Canada
800-361-0352
https://www.crescitatherapeutics.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno:
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Mr. Serge Verreault B.A., M.B.A. | President, CEO & Director | 287,54k | N/D | N/D |
| Mr. Jose DaRocha C.A., CPA | Chief Financial Officer | 208,23k | N/D | N/D |
Descrizione
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations that can deliver actives into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; a development and commercialization license agreement with Taro Pharmaceuticals Inc.; and a distribution and promotion agreement with FILLMED. Crescita Therapeutics Inc. was founded in 2016 and is headquartered in Laval, Canada.
Governance aziendale
L'ISS Governance QualityScore di Crescita Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.
